Malignant tumor of the lung
Conditions
Interventions
Experimental Group:Functional lung avoids radiotherapy
Sponsors
The Second Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years, any gender; 2.Pathologically confirmed malignant pulmonary tumor (non-small cell lung cancer, small cell lung cancer, or pulmonary metastases) requiring thoracic radiotherapy; 3.Planned to receive standard thoracic radiotherapy and able to complete routine pre-treatment 4DCT simulation (prescribed dose >= 45 Gy); 4.Adequate organ function to tolerate radiotherapy; ECOG performance status 0–1; 5.No absolute contraindications to pulmonary function (e.g., patients with moderate COPD may be included if clinically assessed to tolerate radiotherapy); 6.Signed informed consent form and voluntary participation;
Exclusion criteria
Exclusion criteria: 1.Special populations: pregnant or breastfeeding women; minors under 18 years of age. Due to the potential harm of radiation to a fetus or infant, women of childbearing potential must have pregnancy excluded before enrollment. 2.Disease conditions: early-stage lung cancer patients planned for stereotactic body radiotherapy (SBRT) (small treatment field and good prognosis, minimal value in functional avoidance); patients with other advanced malignancies requiring priority treatment. 3.Prior treatment history: previous high-dose chest radiotherapy to the same region resulting in lung tolerance near its maximum limit (unsafe for re-irradiation); participation in other interventional clinical trials in the recent past that could interfere with this study’s results. 4.Severe comorbidities: uncontrolled serious cardiopulmonary disease (e.g., decompensated heart failure, active severe pulmonary infection) rendering radiotherapy excessively risky; psychiatric or cognitive disorders preventing compliance with treatment or follow-up. 5.Other circumstances deemed unsuitable for participation by the investigators. Borderline cases will be carefully reviewed by the study team to ensure participant safety.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The dosimetric improvement ranges of V10, V20, V30, MLD, etc. in the high-function lung area; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of grade 2 radiation pneumonitis (CTCAE v5.0);FEV? /DLCO variation;Quality of life (lung function-related) score; | — |
Countries
China
Contacts
Public ContactZhengzhou Yang
The Second Affiliated Hospital of Chongqing Medical University
Outcome results
None listed